Skip to content

The TOUCAN trial: a randomised, blind, clinical trial that compares the effects of TOUpet fundopliCAtion and Nissen fundoplication on the mechanics of the gastroesophageal junction.

The TOUCAN trial: a randomised, blind, clinical trial that compares the effects of TOUpet fundopliCAtion and Nissen fundoplication on the mechanics of the gastroesophageal junction. - TOUCAN trial

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON33114
Enrollment
50
Registered
2009-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux reflux disease

Interventions

After randomization, twenty-five patients will undergo laparoscopic Toupet fundoplication and will be compared to twenty-five patients who will undergo laparoscopic Nissen fundoplication.

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Persisting reflux related complaints for over 6 months despite double dose PPI use ( * 40 mg omeprazole / 24 hours or comparable therapy) and/or refusal of taking lifelong antireflux medication. - Pathological ambulatory 24 hour pH test (total acid exposure > 5.8% and/or symptom association probability (SAP) > 95%) - Adults - Healthy patients with no disease other than the disorder for which the operations carried out and patients with mild to moderate systemic disease caused by the surgical condition or by other pathological processes, medically well-controlled (American Society of Anaesthesiologists classification of preoperative risk 1 or 2)

Exclusion criteria

Exclusion criteria: - History of gastric or esophageal surgery - Esophageal aperistalsis - Achalasia - Esophageal spasms - Contraindications against undergoing laparoscopic antireflux surgery - Patients with a psychiatric disease or other conditions making them incapable of filling out the questionnaires or completing the esophageal function tests.

Design outcomes

Secondary

MeasureTime frame
1. Dysphagia (Mayo Dysphagia Questionaire) 2. Esophageal transit time - Esophageal transit time and esophageal diameter on timed barium esophagram - Esophagogastric transit time on impedance monitoring 3. Esophageal motility on high-resolution manometry 4. Compliance of the EGJ, quantified as the cross-sectional area of EGJ after volume controlled distension, using a Functional Lumen Imaging Probe (FLIP) 5. Severe dysphagia, defined as: dysphagia needing reintervention (balloon dilatation or surgical reintervention), causing weight loss or requiring diet changes. 6. Reflux symptoms (RDQ) 7. Quality of Life (SF-36)

Primary

MeasureTime frame
Residual relaxation pressure of the EGJ on high-resolution manometry.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)